Jonathan Juco

5.8k total citations · 3 hit papers
24 papers, 2.6k citations indexed

About

Jonathan Juco is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jonathan Juco has authored 24 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Jonathan Juco's work include Cancer Immunotherapy and Biomarkers (12 papers), Lymphoma Diagnosis and Treatment (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Jonathan Juco is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Lymphoma Diagnosis and Treatment (4 papers) and Radiomics and Machine Learning in Medical Imaging (3 papers). Jonathan Juco collaborates with scholars based in United States, Canada and United Kingdom. Jonathan Juco's co-authors include Jared Lunceford, Kenneth Emancipator, Shilpa Gupta, Laura Q.M. Chow, Kumudu Pathiraja, Barbara Burtness, Veena Shankaran, Kei Muro, Ravit Geva and Talia Golan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Jonathan Juco

23 papers receiving 2.6k citations

Hit Papers

Pembrolizumab for patients with PD-L1-positive advanced g... 2016 2026 2019 2022 2016 2017 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
    2016 848 citations Kei Muro, Hyun Cheol Chung et al. The Lancet Oncology profile →
  2. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    2017 453 citations Jennifer H. Yearley, Christopher J. Gibson et al. Clinical Cancer Research profile →
  3. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
    2018 378 citations Karina Kulangara, Nancy R. Zhang et al. Archives of Pathology & Laboratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Juco United States 16 1.9k 1.0k 737 610 375 24 2.6k
Claudia Pauligk Germany 24 1.4k 0.7× 2.0k 2.0× 1.2k 1.6× 230 0.4× 255 0.7× 117 2.9k
W. Ruka Poland 25 1.4k 0.8× 1.4k 1.4× 493 0.7× 287 0.5× 233 0.6× 58 2.6k
Yoshikazu Uenosono Japan 34 1.4k 0.7× 2.0k 1.9× 1.3k 1.8× 309 0.5× 199 0.5× 142 3.5k
Anthony P. Conley United States 26 774 0.4× 1.0k 1.0× 189 0.3× 273 0.4× 240 0.6× 119 1.9k
Kevin Norwood United States 22 1.3k 0.7× 504 0.5× 779 1.1× 180 0.3× 363 1.0× 38 1.8k
Armelle Dufresne France 19 1.1k 0.6× 1.1k 1.1× 216 0.3× 167 0.3× 481 1.3× 103 2.2k
Tatsuya Yoshida Japan 23 1.3k 0.7× 1.3k 1.3× 556 0.8× 215 0.4× 90 0.2× 168 2.5k
Bernadette Liegl‐Atzwanger Austria 25 863 0.5× 1.3k 1.3× 528 0.7× 118 0.2× 191 0.5× 109 2.2k
H Arnholdt Germany 23 943 0.5× 637 0.6× 540 0.7× 133 0.2× 149 0.4× 75 2.0k
Myles Smith United Kingdom 22 892 0.5× 872 0.8× 528 0.7× 80 0.1× 258 0.7× 79 1.8k

Countries citing papers authored by Jonathan Juco

Since Specialization
Citations

This map shows the geographic impact of Jonathan Juco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Juco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Juco more than expected).

Fields of papers citing papers by Jonathan Juco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Juco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Juco. The network helps show where Jonathan Juco may publish in the future.

Co-authorship network of co-authors of Jonathan Juco

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Juco. A scholar is included among the top collaborators of Jonathan Juco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Juco. Jonathan Juco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vainer, Gilad W., Sunil Badve, Fernando Augusto Soares, et al.. (2025). Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications. Frontiers in Oncology. 15. 1581275–1581275.
2.
Kim, Jimin, Binnari Kim, Eunji Kim, et al.. (2020). Interchangeability of PD-L1 laboratory-developed test by 22C3 antibody concentrate among ihc platforms in gastric cancer. Pathology. 52. S120–S120. 1 indexed citations
3.
Cohen, Ezra E.W., Kevin J. Harrington, Denis Soulières, et al.. (2019). Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040. Annals of Oncology. 30. v452–v453. 3 indexed citations
4.
Kulangara, Karina, Nancy R. Zhang, Ellie Corigliano, et al.. (2018). Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Archives of Pathology & Laboratory Medicine. 143(3). 330–337. 378 indexed citations breakdown →
5.
Ilié, Marius, Jonathan Juco, Lingkang Huang, et al.. (2018). Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients. Cancer Cytopathology. 126(4). 264–274. 65 indexed citations
6.
Yearley, Jennifer H., Christopher J. Gibson, Ni Yu, et al.. (2017). PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research. 23(12). 3158–3167. 453 indexed citations breakdown →
7.
Ilié, Marius, Shirin Khambata‐Ford, Christiane Copie‐Bergman, et al.. (2017). Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE. 12(8). e0183023–e0183023. 79 indexed citations
8.
Plimack, Elizabeth R., Joaquim Bellmunt, Shilpa Gupta, et al.. (2017). Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. The Lancet Oncology. 18(2). 212–220. 259 indexed citations
9.
Muro, Kei, Hyun Cheol Chung, Veena Shankaran, et al.. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology. 17(6). 717–726. 848 indexed citations breakdown →
10.
Plimack, Elizabeth R., Joaquim Bellmunt, Shilpa Gupta, et al.. (2015). Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.. Journal of Clinical Oncology. 33(15_suppl). 4502–4502. 90 indexed citations
11.
Scheithauer, Bernd W., Jonathan Juco, Éva Horváth, et al.. (2009). Primary Pituitary Lymphoma: A Histological, Immunohistochemical, and Ultrastructural Study with Literature Review. Endocrine Pathology. 20(1). 46–49. 13 indexed citations
12.
Haitsma, Jack J., Marcus J. Schultz, J. W. Kuiper, et al.. (2008). Ventilator-induced coagulopathy in experimentalStreptococcus pneumoniaepneumonia. European Respiratory Journal. 32(6). 1599–1606. 22 indexed citations
13.
Kovács, Kálmán, C. David Bell, Jonathan Juco, Fabio Rotondo, & Jennifer Anderson. (2007). Parathyroid Chief Cell Adenoma Associated with Massive Chronic Parathyroiditis in a Woman with Hyperparathyroidism. Endocrine Pathology. 18(1). 42–45. 6 indexed citations
14.
Juco, Jonathan, E Horváth, Harley S. Smyth, Fabio Rotondo, & Kálmán Kovács. (2007). Hemangiopericytoma of the sella mimicking pituitary adenoma: case report and review of the literature. Clinical Neuropathology. 26(11). 288–293. 8 indexed citations
15.
Li, Shiyong, Jonathan Juco, Karen P. Mann, & Jeannine T. Holden. (2004). Flow Cytometry in the Differential Diagnosis of Lymphocyte-Rich Thymoma From Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. American Journal of Clinical Pathology. 121(2). 268–274. 44 indexed citations
16.
Li, Shiyong, Jonathan Juco, Karen P. Mann, & Jeannine T. Holden. (2004). Flow Cytometry in the Differential Diagnosis of Lymphocyte-Rich Thymoma From Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. American Journal of Clinical Pathology. 121(2). 268–274. 39 indexed citations
17.
Juco, Jonathan, et al.. (2003). Immunophenotypic Analysis of Anaplastic Large Cell Lymphoma by Flow Cytometry. American Journal of Clinical Pathology. 119(2). 205–212. 15 indexed citations
18.
Juco, Jonathan, et al.. (2003). Immunophenotypic Analysis of Anaplastic Large Cell Lymphoma by Flow Cytometry. American Journal of Clinical Pathology. 119(2). 205–212. 65 indexed citations
19.
Nagasaka, Tetsuro, et al.. (2000). Anaplastic Large Cell Lymphomas Presented as Bone Lesions: A Clinicopathologic Study of Six Cases and Review of the Literature. Modern Pathology. 13(10). 1143–1149. 32 indexed citations
20.
Lai, Raymond, et al.. (2000). Flow Cytometric Detection of CD79a Expression in T-Cell Acute Lymphoblastic Leukemias. American Journal of Clinical Pathology. 113(6). 823–830. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Pauligk Breakdown of academic impact, for papers by W. Ruka Breakdown of academic impact, for papers by Yoshikazu Uenosono Breakdown of academic impact, for papers by Anthony P. Conley Breakdown of academic impact, for papers by Kevin Norwood Breakdown of academic impact, for papers by Armelle Dufresne Breakdown of academic impact, for papers by Tatsuya Yoshida Breakdown of academic impact, for papers by Bernadette Liegl‐Atzwanger Breakdown of academic impact, for papers by H Arnholdt Breakdown of academic impact, for papers by Myles Smith
Rankless by CCL
2026